Nicole W. Simons

Nicole W. Simons

Auto-generated profile, based on publicly available information

Nicole W. Simons

Icahn School of Medicine at Mount Sinai

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Cell
Verified
Journal Article
Closed access
CGConor N. Gruber
Conor N. Gruber
RPRoosheel S. Patel
Roosheel S. Patel
RTRebecca Trachtman
Rebecca Trachtman
LLLauren Lepow
Lauren Lepow
FAFatima Amanat
Fatima Amanat
DBDusan Bogunovic
Dusan Bogunovic

14 September 2022 in Science Translational Medicine
Verified
Journal Article
Open access
SCSteven T. Chen
Steven T. Chen
MPMatthew Park
Matthew Park
DVDiane Marie Del Valle
Diane Marie Del Valle
MBMark Buckup
Mark Buckup
ATAlexandra Tabachnikova
Alexandra Tabachnikova
MMMiriam Merad
Miriam Merad
Although it has been more than 2 years since the start of the coronavirus disease 2019 (COVID-19) pandemic, COVID-19 continues to be a worldwide health crisis. Despite the development of preventive vaccines, therapies to treat COVID-19 and other inflammatory diseases remain a major unmet need in medicine. Our study sought to identify drivers of disease severity and mortality to develop tailored immunotherapy strategies to halt disease progression. We assembled the Mount Sinai COVID-19 Biobank, which was composed of almost 600 hospitalized patients followed longitudinally through the peak of the pandemic in 2020. Moderate disease and survival were associated with a stronger antigen presentation and effector T cell signature. In contrast, severe disease and death were associated with an altered antigen presentation signature, increased numbers of inflammatory immature myeloid cells, and extrafollicular activated B cells that have been previously associated with autoantibody formation. In severely ill patients with COVID-19, lung tissue–resident alveolar macrophages not only were drastically depleted but also had an altered antigen presentation signature, which coincided with an influx of inflammatory monocytes and monocyte-derived macrophages. In addition, we found that the size of the alveolar macrophage pool correlated with patient outcome and that alveolar macrophage numbers and functionality were restored to homeostasis in patients who recovered from COVID-19. These data suggest that local and systemic myeloid cell dysregulation are drivers of COVID-19 severity and modulation of alveolar macrophage numbers and activity in the lung may be a viable therapeutic strategy for the treatment of critical inflammatory lung diseases.

8 December 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
RTRyan C. Thompson
Ryan C. Thompson
NSNicole W. Simons
Nicole W. Simons
LWLillian Wilkins
Lillian Wilkins
ECEsther Cheng
Esther Cheng
DVDiane Marie Del Valle
Diane Marie Del Valle
NBNoam D. Beckmann
Noam D. Beckmann
Post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are debilitating, clinically heterogeneous and of unknown molecular etiology. A transcriptome-wide investigation was performed in 165 acutely infected hospitalized individuals who were followed clinically into the post-acute period. Distinct gene expression signatures of post-acute sequelae were already present in whole blood during acute infection, with innate and adaptive immune cells implicated in different symptoms. Two clusters of sequelae exhibited divergent plasma-cell-associated gene expression patterns. In one cluster, sequelae associated with higher expression of immunoglobulin-related genes in an anti-spike antibody titer-dependent manner. In the other, sequelae associated independently of these titers with lower expression of immunoglobulin-related genes, indicating lower non-specific antibody production in individuals with these sequelae. This relationship between lower total immunoglobulins and sequelae was validated in an external cohort. Altogether, multiple etiologies of post-acute sequelae were already detectable during SARS-CoV-2 infection, directly linking these sequelae with the acute host response to the virus and providing early insights into their development.

3 November 2022 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
GBGuillaume Butler-Laporte
Guillaume Butler-Laporte
GPGundula Povysil
Gundula Povysil
JKJack A. Kosmicki
Jack A. Kosmicki
ECElizabeth T. Cirulli
Elizabeth T. Cirulli
TDTheodore Drivas
Theodore Drivas
JRJ Brent Richards
J Brent Richards
Host genetics is a key determinant of COVID-19 outcomes. Previously, the COVID-19 Host Genetics Initiative genome-wide association study used common variants to identify multiple loci associated with COVID-19 outcomes. However, variants with the largest impact on COVID-19 outcomes are expected to be rare in the population. Hence, studying rare variants may provide additional insights into disease susceptibility and pathogenesis, thereby informing therapeutics development. Here, we combined whole-exome and whole-genome sequencing from 21 cohorts across 12 countries and performed rare variant exome-wide burden analyses for COVID-19 outcomes. In an analysis of 5,085 severe disease cases and 571,737 controls, we observed that carrying a rare deleterious variant in the SARS-CoV-2 sensor toll-like receptor TLR7 (on chromosome X) was associated with a 5.3-fold increase in severe disease (95% CI: 2.75–10.05, p = 5.41x10-7). This association was consistent across sexes. These results further support TLR7 as a genetic determinant of severe disease and suggest that larger studies on rare variants influencing COVID-19 outcomes could provide additional insights.

9 September 2026 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
RCRenata Gonzalez Chong
Renata Gonzalez Chong
DODeborah Obiajulu
Deborah Obiajulu
HTHeather Thibeau
Heather Thibeau
SSSafrana Safa
Safrana Safa
MGMackenzie Glanville
Mackenzie Glanville
NSNicole W. Simons
Nicole W. Simons
Background: Artificial intelligence (AI) is explored as a tool to expand access to mental health care, offering support and self-disclosure. To date, the perspectives of individuals with schizophrenia on AI have been absent from the medical literature. This exploratory study represents an effort to report schizophrenia patient perspectives on AI chatbots through a focus group. Methods: We conducted an exploratory, cross-sectional, qualitative study using semi-structured focus groups at a large academic health center in New York City. Participants included patients with schizophrenia spectrum disorders ( n = 17), caregivers ( n = 7), and providers ( n = 4). Discussions explored familiarity with AI, privacy, and perceived utility of a hypothetical AI companion tool. Transcripts were analyzed using thematic analysis. Results: Five themes were identified in this exploratory analysis: (1) ‘Available When No One Else Is’, reflecting participants’ recognition of AI as a potentially accessible source of between-visit support; (2) ‘What Would It Do?’ capturing uncertainty about AI’s role; (3) ‘How Can I Trust It?’ highlighting trust as the central barrier, shaped by privacy concerns and schizophrenia-specific vulnerabilities; (4) ‘A Tool, Not a Therapist’, emphasizing that AI was acceptable only as a supplement to, not a replacement for, human care; and (5) ‘Keep It Low-Risk’, describing the narrow range of acceptable use cases, limited to supportive functions. Conclusions: These exploratory findings suggest that AI is perceived as both a promising adjunct to care and a potential risk in schizophrenia. Implementation should emphasize transparency, trust, and clear boundaries, with AI designed to support, not replace, existing care.

12 October 2026 in Biological Psychiatry
Verified
Journal Article
Open access
NSNicole W. Simons
Nicole W. Simons
VPVibhuti Patel
Vibhuti Patel
HLHaoyuan Li
Haoyuan Li
SIShruti Iyer
Shruti Iyer
YZYichen Zhong
Yichen Zhong
ACAlexander W. Charney
Alexander W. Charney
Few gene-disease associations identified by human genetic studies lead to new drugs that advance to first-in-human trials. Schizophrenia exemplifies this translational gap: thousands of gene-disease associations have been reported, but antipsychotics act via mechanisms introduced in the 1950s. To close the gap, clinical research strategies are needed that generalize across genes and diseases. Candidate drug targets were defined as genes linked to schizophrenia by population-based studies. Clinical validation of candidate targets was performed through family-based studies. The molecular effects of clinically validated targets were confirmed by correcting mutations in the neurons from affected family members. For one validated target, a messenger RNA (mRNA) drug was developed, and pre-clinical studies of the drug were performed. Carriers of rare protein-truncating variants (PTVs) in schizophrenia risk genes were identified in 30,813 patients of a US healthcare system. These included two female relatives with a rare PTV in GRIA3, which encodes the GluA3 subunit of the AMPA-type glutamate receptor. Further investigation of the family found an X-linked pattern of inheritance between the PTV and severe mental illness. Correction of the PTV in neurons of affected male family members restored GRIA3 expression. A GRIA3 mRNA drug was developed and in mice was well tolerated, resulted in broad brain expression of GluA3, and rescued behavioral abnormalities in a pharmacologically induced psychosis model (MK-801). Further development toward clinical evaluation of a novel GRIA3 mRNA drug to treat schizophrenia is warranted.